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67.6% were male. Based upon the questionnaire, 36.1%
of patients reported nonadherence. Lower adherence rate
(49.1%) was obtained when comparing medications 
prescribed at discharge to medications documented at
follow-up. Based on the questionnaire, the more medica-
tion prescribed, the greater the adherence (p = 0.02).
Trend tests of adherence over increasing number of 
medications were positive in all medication classes 
(beta-blockers, ACE inhibitors, anticoagulants, and lipid
lowering drugs). Multivariate models show the similar
trend when adjusted for age and gender. Adherence 
also increased with more documented comorbidities (p =
0.01). When comparing medications prescribed to med-
ications at follow-up there were no signiﬁcant predictors
of adherence.
CONCLUSIONS: Nonadherence is frequent in patients
after an MI (36%). Utilizing a medication adherence
questionnaire to assess adherence is better than merely
comparing medication lists at two different points in time.
Better adherence to all four evidence-based therapies after
an MI is seen in patients prescribed more medications 
and with more disease states. Higher adherence may be
related to a recent major health event, more recent edu-
cation on treatment beneﬁts, and/or to a focus on reha-
bilitation. This study demonstrates the need for a larger,
broader study that includes health beliefs, psychosocial
assessment, and other patient factors that may inﬂuence
compliance.
ARTHRITIS & OSTEOPOROSIS—Clinical Outcomes
Presentation
PAO1
CARDIORENAL EFFECTS AND COSTS OF COX-
2 INHIBITORS IN A MANAGED CARE
ORGANIZATION
Yu-Isenberg KS1, Leslie RS1, Chang EY1,White TJ1, Bailey KL2
1Prescription Solutions, Costa Mesa, CA, USA; 2Pharmacia
Corporation, Peapack, NJ, USA
Arthritis—rheumatoid and osteoarthritis—is one of the
most prevalent chronic conditions affecting nearly 50%
of persons over the age of 65.
OBJECTIVES: The objective of this study was to
compare cardiorenal events and costs between two COX-
2 inhibitors—celecoxib and rofecoxib.
METHODS: This was a retrospective analysis of medical
and pharmacy claims. All patients newly started on a
COX-2 inhibitor during 7/1/99 to 6/30/00 were identiﬁed
and followed for 6 months before and after the initial
COX-2 prescription. Incident cardiorenal events were
attributable to a COX-2 if there was an ICD-9 diagnosis
code within 45 days after the last days supply of the 
prescription.
RESULTS: A total of 20,514 patients were newly pre-
scribed celecoxib (n = 12,487) or rofecoxib (n = 8,027).
Mean age was 65 (+/-15) and 68% were female. Primary
indication for COX-2 was pain (55%), followed by
osteoarthritis (23%), other arthritis (17%), and rheuma-
toid arthritis (6%). There were no signiﬁcant differences
in baseline cardiorenal history and medication use
(antiarthritic, antihypertensive, and GI-related) between
the two cohorts. Among the baseline hypertensive
patients, those on rofecoxib were 34% more likely to
experience an incident cardiorenal event than patients on
celecoxib, adjusting for age, gender, comorbidity, indica-
tion and dosage (OR = 1.34; p = 0.007). Results were
similar for the baseline non-hypertensive patients, with
those on rofecoxib reporting a higher risk of new car-
diorenal events (OR = 1.18; p = 0.0009). Although not
statistically signiﬁcant, patients on rofecoxib incurred
slightly higher total health care costs than those on cele-
coxib ($8,188 vs. $7,540; p = 0.0867).
CONCLUSION: The risk of cardiorenal events was 
signiﬁcantly higher in rofecoxib-treated patients than
celecoxib-treated patients. There were no statistically sig-
niﬁcant differences in total costs between the two COX-
2 inhibitors, although celecoxib-treated patients incurred
slightly lower total health care costs.
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OSTEOPOROTIC WOMEN WITH INCIDENT
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Osteoporosis affects 4–6 million women in the USA.
OBJECTIVES: The objective of this study was two-fold:
1) to evaluate treatment patterns of care associated 
with an incident fracture in postmenopausal women in a
managed care organization and 2) to estimate the inci-
dence of subsequent fractures by age.
METHODS: This was a retrospective analysis of medical
and pharmacy claims. Women aged 55 or older, with a
primary or secondary diagnosis of a new bone fracture
during calendar year 1999, and continuously enrolled in
the health plan were included in the sample. All claims
12-months before and 15-months after index fracture
date were evaluated for medication use and subsequent
fractures.
RESULTS: A total of 19,720 women had incident bone
fractures. Mean age was 78 years (+/-9.4). Of these
19,720 women, 90% had nonvertebral fractures, mainly
hip and wrist, and 10% had vertebral fractures. Overall
use of osteoporosis therapy, anytime before and after
index fracture, was 24% and 29%, respectively. Of the
women receiving therapy after fracture, 65% were 
prescribed estrogen, 28% bisphosphonates, 17% nasal
calcitonin, 14% combination therapy, primarily a bis-
phosphonate plus estrogen, and 5% raloxifene. Only
25% of treated women remained on therapy for at least
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12 months. The chi-square test for trend revealed a 
signiﬁcant trend for a decreasing rate of treatment with
increasing age (p < 0.0001). During the follow-up period,
34% of women had subsequent fractures. Furthermore,
there was a signiﬁcant risk of subsequent fractures with
increasing age (p < 0.0001).
CONCLUSION: Evidence from the published literature
show that the risk of fracture increases with age, partic-
ularly among those with prior fracture events. In this
study, only one-fourth of the study women received osteo-
porotic therapy after an incident bone fracture. Given the
magnitude of the ﬁnancial, physical, and psychosocial
consequences of osteoporotic fractures, more attention
should be given to the treatment of osteoporosis.
ARTHRITIS & OSTEOPOROSIS—Economic
Outcomes Presentations
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OBJECTIVES: To provide a comprehensive assessment 
of the cost-effectiveness of rofecoxib relative to diclofenac
therapy, the main NSAID used in Australia. The evalua-
tion employs cost-utility and cost-effectiveness analysis
from a health system perspective with the endpoints being
the incremental cost per quality adjusted life year (QALY)
gained and incremental cost per life year saved (LYS).
METHODS: A Markov process was used to advance
patients through seven health states in daily cycles over a
period of one year. The modelled population is based on
typical osteoarthritis patients in Australia (approximately
71% women, mean age: 63 years). Clinical data on the
incidence of gastrointestinal adverse events (Perforations/
ulcers/ bleeds or other gastrointestinal adverse events)
were derived by systematic review and meta-analysis of
randomised trials. Utility values were obtained using the
EQ-5D and a survey of health professionals. Resource use
and valuation included drug costs and the costs associ-
ated with the treatment of gastrointestinal adverse events.
Univariate and multivariate sensitivity analysis was
undertaken.
RESULTS: In a mixed population of patients with
osteoarthritis, the incremental cost per QALY associated
with rofecoxib compared to diclofenac is $A18,691.
Simply focusing on mortality, the cost per death avoided
amounts to $A67,092. Assuming that 13.2 discounted life
years would have been saved per death avoided (life
expectancy of typical osteoarthritis patient). The associ-
ated cost per LYS could be as low as $A5,097. Sensitiv-
ity analyses indicated that rofecoxib offers favourable
cost-effectiveness according to Australian National
Health and Medical Research Council (NHMRC) guide-
lines. The maximum incremental cost per QALY gener-
ated when key assumptions were altered in sensitivity
analysis was always less than $A70,000.
CONCLUSIONS: The incremental QALY and LYS out-
comes derived from the modelled evaluation are well
within the bounds considered cost effective by Australian
guidelines. Improved quality of life make rofecoxib a cost
effective alternative for patients with osteoarthritis.
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COST ANALYSIS OF A 12-WEEK CYCLE OF
THERAPY WITH CELECOXIB VS.
CONVENTIONAL NSAIDS IN PATIENTS WITH
OSTEOARTHRITIS
Chiroli S, Roggeri DP
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Osteoarthritis (OA) has an high prevalence rate in 
Italy. Traditional NSAIDs, the commonest symptomatic
OA treatment, cause gastrointestinal (GI) side effects,
varying from milder symptoms of GI intolerance to life-
threatening GI perforation obstruction and bleeding
(POB). Celecoxib has demonstrated a much better GI
safety proﬁle than NSAIDs, but it is more expensive.
OBJECTIVES: To estimate the cost from the Italian
national health service (INHS) perspective of a 12-week
cycle of therapy in OA patients with celecoxib or
NSAIDs.
METHODS: A decision-tree was used to estimate over
12 weeks the costs of two alternative therapies: celecoxib
200mg/day (€1.38/day) and NSAIDs (€0.41/day) whose
cost was calculated as the mean of the ﬁrst ten prescribed
NSAIDs in Italy in year 2000, at the mean dosage. The
time frame was chosen as the most representative of the
Italian physicians prescription habits. Probabilities of side
effects, derived from clinical trials, were: Celecoxib, GI
intolerance 0.078, Anemia 0.0015, Ulcer 0.0085, POB
0.001; NSAIDs, GI intolerance 0.12, Anemia 0.0055,
Ulcer 0.0315, POB 0.008. Probabilities of hospitaliza-
tion, derived from Italian literature, were: GI intolerance,
0; Anemia, 0.2, Ulcer 0.3, POB, 1. Cost to treat the events
were estimated using the INHS tariffs and DRGs and
were: GI intolerance, €138; Anemia without hospitaliza-
tion, €432; anemia with hospitalization, €3,908; Ulcer
without hospitalization, €491, Ulcer with hospitalization,
€2,530; POB, €10,809.34.
RESULTS: The costs of the alternative therapies were
€148.56 for celecoxib 200mg/day and €178.41 for
NSAIDs.
CONCLUSIONS: Celecoxib is more expensive than the
commonest prescribed NSAIDs in Italy; nevertheless,
NSAIDs GI side effect have high prevalence and resource
consumption, included a high rate of hospitalization, and
a related considerable cost load for INHS. Therefore, the
correct prescription of celecoxib may result in global cost-
savings for the payer.
